| Application no. and date | 19163698.4 (espacenet) (Federated) (European Patent Register), 20060818 | | Patent/reg. no. and date | DK/EP 3524261, 20231213 | | Publication date | 20190814 | | Priority no. and date | US 70960405 P, 20050819, US 77921606 P, 20060303 | | EP pub. no. and date |
EP 3524261 20190814 | | Effective date | | | Applicant/owner | Amylin Pharmaceuticals, LLC, 9360 Towne Centre Drive
San Diego, CA 92121, US,
AstraZeneca Pharmaceuticals LP, 1800 Concord Pike
Wilmington, DE, US | | Applicant ref. no. | P83799DK01 | | Inventor | Fineman, Mark, c/o Amylin Pharmaceuticals, LLC
9360 Towne Centre Drive
San Diego, CA California 92121, US,
Macconell, Leigh, c/o Amylin Pharmaceuticals, LLC
9360 Towne Centre Drive
San Diego, CA California 92121, US,
Taylor, Kristin, c/o Amylin Pharmaceuticals, LLC
9360 Towne Centre Drive
San Diego, CA California 92121, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup | | Opponent | | | IPC Class | A61K 38/26 (2006.01) , A61K 9/00 (2006.01) , A61P 3/04 (2006.01) , A61P 3/10 (2006.01) | | Title | EXENDIN TIL ANVENDELSE TIL BEHANDLING AF DIABETES OG REDUKTION AF KROPSVÆGT | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | Rettet DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
